Applied Genetic Technologies Corporation

Symbol: AGTC




Market price today

  • -1.5194

    P/E Ratio

  • 0.0008

    PEG Ratio

  • 24.86M

    MRK Cap

  • 0.00%

    DIV Yield

Applied Genetic Technologies Corporation (AGTC) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


General Outlook

In simple terms, Applied Genetic Technologies Corporation has 67.632 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 1.000% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -97.902%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -51.738%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.293% return, is a testament to Applied Genetic Technologies Corporation's adeptness in optimizing resource deployment. Applied Genetic Technologies Corporation's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.536%. Furthermore, the proficiency of Applied Genetic Technologies Corporation in capital utilization is underscored by a remarkable -1.035% return on capital employed.

Stock Prices

Applied Genetic Technologies Corporation's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $0.4125, while its low point bottomed out at $0.396. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Applied Genetic Technologies Corporation's stock market.

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Ms. Susan Washer
Full-time employees:102
Address:14193 Nw 119Th Terrace, Suite #10

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.

Frequently Asked Question

How many company shares are outstanding in 2023?

There are stock number shares outstanding of Applied Genetic Technologies Corporation (AGTC) on the NASDAQ in 2023.

What is P/E ratio of enterprise in 2023?

The current P/E ratio of enterprise is -1.519 in 2023.

What is the ticker symbol of Applied Genetic Technologies Corporation stock?

The ticker symbol of Applied Genetic Technologies Corporation stock is AGTC.

What is company IPO date?

IPO date of Applied Genetic Technologies Corporation is 2014-03-27.

What is company current share price?

Current share price is 0.368 USD.

What is stock market cap today?

The market cap of stock today is 24861596.000.

What is PEG ratio in 2023?

The current 0.001 is 0.001 in 2023.

What is the number of employees in 2023?

In 2023 the company has 102.